The assessment of data mining for the prediction of therapeutic outcome in 3719 Egyptian patients with chronic hepatitis C.

INTRODUCTION Decision-tree analysis; a core component of data mining analysis can build predictive models for the therapeutic outcome to antiviral therapy in chronic hepatitis C virus (HCV) patients. AIM To develop a prediction model for the end virological response (ETR) to pegylated interferon PEG-IFN plus ribavirin (RBV) therapy in chronic HCV patients using routine clinical, laboratory, and histopathological data. PATIENTS AND METHODS Retrospective initial data (19 attributes) from 3719 Egyptian patients with chronic HCV presumably genotype-4 was assigned to model building using the J48 decision tree-inducing algorithm (Weka implementation of C4.5). All patients received PEG-IFN plus RBV at Cairo-Fatemia Hospital, Cairo, Egypt in the context of the national treatment program. Factors predictive of ETR were explored and patients were classified into seven subgroups according to the different rates of ETR. The universality of the decision-tree model was subjected to a 10-fold cross-internal validation in addition to external validation using an independent dataset collected of 200 chronic HCV patients. RESULTS At week 48, overall ETR was 54% according to intention to treat protocol. The decision-tree model included AFP level (<8.08 ng/ml) which was associated with high probability of ETR (73%) followed by stages of fibrosis and Hb levels according to the patients' gender followed by the age of patients. CONCLUSION In a decision-tree model for the prediction for antiviral therapy in chronic HCV patients, AFP level was the initial split variable at a cutoff of 8.08 ng/ml. This model could represent a potential tool to identify patients' likelihood of response among difficult-to-treat presumably genotype-4 chronic HCV patients and could support clinical decisions regarding the proper selection of patients for therapy without imposing any additional costs.

[1]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[2]  M. Kurosaki,et al.  Predictors of Virological Response to a Combination Therapy with Pegylated Interferon Plus Ribavirin Including Virus and Host Factors , 2010, Hepatitis research and treatment.

[3]  C. Sarrazin,et al.  Treatment predictors of a sustained virologic response in hepatitis B and C. , 2008, Journal of hepatology.

[4]  J. Bukh,et al.  Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study , 2011, BMC infectious diseases.

[5]  Andrew H Talal,et al.  Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum α‐fetoprotein , 2004, Liver international : official journal of the International Association for the Study of the Liver.

[6]  Raymond T Chung,et al.  Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. , 2005, Journal of hepatology.

[7]  M. Abdel-hamid,et al.  Hepatitis C virus (HCV) infection in a community in the nile delta: Population description and HCV prevalence , 2000, Hepatology.

[8]  I. Sartori Early Recognition of Hepatocellular Carcinoma Based on Altered Profiles of Alpha-Fetoprotein: , 1994 .

[9]  M. Kurosaki,et al.  Sequences in the interferon sensitivity‐determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG‐interferon plus ribavirin: Data mining analysis , 2011, Journal of medical virology.

[10]  N. Enomoto,et al.  Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response. , 2008, Gastroenterology.

[11]  Wei-Yin Loh,et al.  Classification and regression trees , 2011, WIREs Data Mining Knowl. Discov..

[12]  J. Ross Quinlan,et al.  C4.5: Programs for Machine Learning , 1992 .

[13]  Yi-Ching Hsieh,et al.  Improved detection of prostate cancer using classification and regression tree analysis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. el-Zayadi,et al.  Response of Hepatitis C Genotype-4 Naïve Patients to 24 Weeks of Peg-Interferon-α2b/Ribavirin or Induction-Dose Interferon-α2b/Ribavirin/Amantadine: A Non-Randomized Controlled Study , 2005, The American Journal of Gastroenterology.

[15]  I. Takei,et al.  Novel statistical classification model of type 2 diabetes mellitus patients for tailor-made prevention using data mining algorithm. , 2002, Journal of epidemiology.

[16]  Paul Gray,et al.  Introduction to Data Mining and Knowledge Discovery , 1998, Proceedings of the Thirty-First Hawaii International Conference on System Sciences.

[17]  Hiroki Ikeda,et al.  A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[18]  A. Way,et al.  Egypt Demographic and Health Survey 2000. , 2009 .

[19]  Y. Shiratori,et al.  Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course? , 2000, Journal of gastroenterology and hepatology.

[20]  K. Shianna,et al.  Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients , 2010, AIDS.

[21]  T. Asselah,et al.  Fibrosis and disease progression in hepatitis C , 2002, Hepatology.

[22]  M LeBlanc,et al.  A review of tree-based prognostic models. , 1995, Cancer treatment and research.

[23]  S. Zeuzem Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well? , 2004, Annals of Internal Medicine.

[24]  E. Anderson Hudson et al. , 1977 .

[25]  Ian H. Witten,et al.  Data mining: practical machine learning tools and techniques, 3rd Edition , 1999 .

[26]  K. Hatakeyama,et al.  Prognostic Groups in Colorectal Carcinoma Patients Based on Tumor Cell Proliferation and Classification and Regression Tree (CART) Survival Analysis , 2006, Annals of surgical oncology.

[27]  Jiawei Han,et al.  Data Mining: Concepts and Techniques , 2000 .

[28]  M. Abdel-hamid,et al.  Response to pegylated interferon alfa‐2a and ribavirin in chronic hepatitis C genotype 4 , 2009, Journal of medical virology.

[29]  A. Amer,et al.  Viral kinetic of HCV genotype‐4 during pegylated interferon alpha 2a: ribavirin therapy , 2008, Journal of viral hepatitis.

[30]  N. Lim,et al.  Clinical Significance of Elevated Alpha-Fetoprotein (AFP) in Patients with Chronic Hepatitis C, but not Hepatocellular Carcinoma , 2004, American Journal of Gastroenterology.

[31]  T. Ide,et al.  A Decrease in AFP Level Related to Administration of Interferon in Patients with Chronic Hepatitis C and a High Level of AFP , 2006, Digestive diseases and sciences.

[32]  Sanaa M Kamal,et al.  Hepatitis C genotype 4: What we know and what we don't yet know , 2008, Hepatology.

[33]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[34]  Stefan Zeuzem Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? , 2004 .

[35]  A. Fontanet,et al.  Serum Alpha-Fetoprotein Predicts Treatment Outcome in Chronic Hepatitis C Patients Regardless of HCV Genotype , 2008, PloS one.

[36]  J. Gornbein,et al.  Phosphorus ans an early predictive factor in patients with acute liver failure1 , 2003, Transplantation.

[37]  Stephen L. Chen,et al.  The Natural History of Hepatitis C Virus (HCV) Infection , 2006, International journal of medical sciences.

[38]  P. Marcellin,et al.  Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4 , 2009, Gut.

[39]  M. Abdel-hamid,et al.  Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[40]  J Sunil Rao,et al.  A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: Implications on the future of cancer staging. , 2002, Surgery.

[41]  M. Kurosaki,et al.  Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis , 2011, Journal of Gastroenterology.

[42]  Md. Parvez Anwar,et al.  324 Results of a randomized clinical trial of genotype-4 infected subjects when treated with standard or pegylated interferon alfa-2B in combination with ribavirin , 2003 .

[43]  S. Paul,et al.  Discovery of novel targets for multi-epitope vaccines: Screening of HIV-1 genomes using association rule mining , 2009, Retrovirology.

[44]  M. Abdel-hamid,et al.  Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C. , 2007, Antiviral therapy.

[45]  S. Mauss,et al.  Estimating the likelihood of sustained virological response in chronic hepatitis C therapy , 2011, Journal of viral hepatitis.

[46]  M. Capobianchi,et al.  The Effect of Age on Response to Therapy With Peginterferon α Plus Ribavirin in a Cohort of Patients With Chronic HCV Hepatitis Including Subjects Older Than 65 Yr , 2007, The American Journal of Gastroenterology.

[47]  N. Tanaka,et al.  Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors , 2008, Hepatology.

[48]  A. Bhalla,et al.  Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. , 1997, Gastroenterology.